You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Trading
Institutions
Fees
Promotions
FAQ
Education
Download
About us
Hong Kong
uSMART
EN
Login/Register
Market News

Market News

HomeMarket NewsDetails

嘉和生物(06998.HK)GB261臨牀試驗完成首例患者給藥

阿思達克 09-09 04:22
嘉和生物－B(06998.HK)公佈，GB261(CD20/CD3雙特異性抗體)的I/II期臨牀試驗已完成中國首例患者給藥。這項臨牀試驗申請於5月獲國家藥品監督管理局默示許可，用於復發或難治性B細胞非霍奇金淋巴瘤(B-NHL)和慢性淋巴細胞白血病/小淋巴細胞淋巴瘤(CLL/SLL)患者的治療。
嘉和生物-B(06998.HK)
Relevant Stocks
嘉和生物-B(06998.HK)
Relevant Recommendation
Business Collaboration
Account Opening

Services

FeesFAQExclusive Trading Tools

About Us

OverviewContact UsMedia Center

Agreement Statement

DisclaimerPrivacy Statement
Contact Us
Customer Service Hotline︰+852 3018 4526
Email︰cs@usmarthk.com
Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong
WhatsApp︰+852 5989 2641
Join the Community：
uSMART-Facebook-Page
uSmart Securities Limited
is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Copyright © 2022 uSMART . All Rights Reserved.